TG Therapeutics | TGTX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Alaunos Therapeutics USD 1.07M 215K 2023-06
Amgen USD 95.64B 94.98B 2026-06
Ardelyx USD 5.6M 160K 2026-03
Arrowhead Research USD 24.56M 716K 2026-06
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Curis USD 178K 441K 2023-12
Gilead Sciences USD 247M 7M 2026-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Novartis USD 462M 119M 2026-06
Novavax USD 5.82M 342K 2025-12
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
TG Therapeutics USD 16.57M 8.91M 2026-06
Verastem USD 382K 33K 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12